Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination

Código QR

Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination

Homero Contreras-Salinas,1 Mariana Barajas-Hernández,1 Leopoldo Martín Baiza-Durán,1 Alan Omar Vázquez-Álvarez,2 Manuel Alejandro Bautista-Castro,1 Lourdes Yolotzin Rodríguez-Herrera1 1Pharmacovigilance Department, Laboratorios Sophia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Contreras-Salinas H, Barajas-Hernández M, Baiza-Durán LM, Vázquez-Álvarez AO, Bautista-Castro MA, Rodríguez-Herrera LY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	adverse drug reactions active pharmacovigilance surveillance glaucoma timolol/brimonidine/dorzolamide. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0461246abb8d42d18a83b40487dc3999
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and tolerability of brinzolamide/brimonidine suspension and prostaglandin analogs in patients previously treated with dorzolamide/timolol solution and prostaglandin analogs
por: Lo JS, et al.
Publicado: (2016)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)

Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
por: Yoshikawa K, et al.
Publicado: (2021)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
por: Hiromitsu Onoe, et al.
Publicado: (2021)

Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits
por: Kamaruddin MI, et al.
Publicado: (2017)

The Effect of Brimonidine 0.1% on Disc Hemorrhage in Primary Open-Angle Glaucoma Patients
por: Nitta K, et al.
Publicado: (2020)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)

Quality assessment of individual case safety reports in pharmacovigilance in Burkina Faso
por: Roamba Nazaire, et al.
Publicado: (2021)

Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon
por: Shen J, et al.
Publicado: (2016)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
por: Wang N, et al.
Publicado: (2020)

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue K, et al.
Publicado: (2018)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi H, et al.
Publicado: (2017)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Farmacovigilancia activa de metoclopramida 10 mg oral en pacientes del Programa de Alivio del Dolor y Cuidados Paliativos o diabetes mellitus tipo 2 en cinco hospitales del Servicio de Salud Viña del Mar-Quillota
por: Frez,Carla, et al.
Publicado: (2018)

Dermoscopic Evaluation of Infantile Hemangioma Treated With Topical Timolol
por: Rubina Jassi, et al.
Publicado: (2020)

Regulation Awareness and Experience of Additional Monitoring among Healthcare Professionals in Finland
por: Andreas Sandberg, et al.
Publicado: (2021)

Safety of Inulin and Sinistrin: Combining Several Sources for Pharmacovigilance Purposes
por: T-V. Bui, et al.
Publicado: (2021)

Effective stakeholder analysis and engagement: a vital strategy for enhanced pharmacovigilance systems in sub-Saharan Africa
por: Babafunso A. Adenuga, et al.
Publicado: (2020)

Pre- and postsynaptic effects of brimonidine on isolated rabbit iris dilator muscles
por: Tatsui S, et al.
Publicado: (2016)

Preliminary evaluation of the efficacy and safety of brimonidine for general anesthesia
por: Chen Bin, et al.
Publicado: (2021)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe N, et al.
Publicado: (2020)

Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension
por: Tamçelik N, et al.
Publicado: (2017)

Spontaneous reporting of adverse drug reactions: nurses’ perception
por: Erefai Ouassima, et al.
Publicado: (2021)

Development of instrument to report and assess causality of adverse events related to herbal medicines
por: Patrícia de Carvalho Mastroianni, et al.

Development of instrument to report and asses causality of adverse events related to herbal medicines
por: Patricia de Carvalho MASTROIANNI, et al.
Publicado: (2017)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue K, et al.
Publicado: (2020)

A 5 year retrospective analysis of adverse drug reactions associated with antimicrobials in a teaching hospital of Andaman and Nicobar islands
por: Mangesh Bankar, et al.
Publicado: (2021)

Nanomedicinal products: a survey on specific toxicity and side effects
por: Brand W, et al.
Publicado: (2017)

THE DADER METHOD FOR PHARMACOTHERAPY FOLLOW-UP AND PHARMACOVIGILANCE IN HEALTH INSTITUTIONS OF COLOMBIA
por: Pedro AMARILES M., et al.
Publicado: (2009)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto K, et al.
Publicado: (2018)

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
por: Pece A, et al.
Publicado: (2016)

Adverse drug reactions of anti-infective drugs for systemic use in Morocco: Pharmaco-Epidemiological study 2008-2016
por: Kharbouch Donia, et al.
Publicado: (2021)

Efficacy Evaluation of 755-nm Long-Pulse Alexandrite Laser Combined with 0.5% Timolol Maleate Eye Drops in the Treatment of Thicker Infantile Hemangioma
por: Wu J, et al.
Publicado: (2021)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis VM, et al.
Publicado: (2018)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Using Population-Based Structures to Actively Monitor AEFIs during a Mass Immunization Campaign—A Case of Measles–Rubella and Polio Vaccines
por: Dan Kajungu, et al.
Publicado: (2021)